Darusentan

Drug Profile

Darusentan

Alternative Names: HMR 4005; LU-135252

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Gilead Sciences
  • Class Antihypertensives; Heart failure therapies; Phenylpropionates; Pyrimidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Arrhythmias; Diabetic angiopathies; Diabetic nephropathies; Heart failure; Ischaemic heart disorders; Renal transplant rejection; Resistant hypertension; Stroke

Most Recent Events

  • 17 Dec 2009 Final efficacy data from a phase III (DAR-312) trial in Resistant hypertension released by Gilead Sciences
  • 16 Sep 2009 Final safety and efficacy data from a phase III (DAR-311) trial in Resistant hypertension released by Gilead Sciences
  • 08 Apr 2009 Preliminary safety and efficacy data from a phase III (DAR-311) trial in Resistant hypertension released by Gilead Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top